Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343966 | 0.90 | JAK1 (0.40) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL23413758 | 0.89 | KRAS (0.50) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29903158 | 0.89 | KRAS (0.50) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29903156 | 0.86 | KRAS (0.46) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL23413429 | 0.86 | KRAS (0.46) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29343969 | 0.86 | KRAS (0.42) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29937018 | 0.86 | KRAS (0.38) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29343959 | 0.86 | KRAS (0.38) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL23413397 | 0.85 | KRAS (0.46) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL29903187 | 0.85 | KRAS (0.46) | KRASJAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | KRAS 1/4885JAK1 1197/4885JAK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.